DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effects of Intravenous (IV) Citalopram on Emotional Brain Activity in Healthy Young and Elderly Adults

Information source: Rotman Research Institute at Baycrest
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy Young and Elderly Volunteers

Intervention: Intravenous Citalopram (Drug); Normal Saline (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Rotman Research Institute at Baycrest

Official(s) and/or principal investigator(s):
Bruce G Pollock, MD PhD FRCPC, Principal Investigator, Affiliation: Centre for Addiction and Mental Health

Overall contact:
Christina E Pataky Forsyth, HBSc, Phone: 416-655-4666, Email: cpataky@research.baycrest.org

Summary

Antidepressant medications known as selective serotonin reuptake inhibitors (SSRIs) are most commonly prescribed to treat depression and anxiety. How antidepressants work on the brain to alter mood and behaviour is not well understood. This study will use a brain scanning technique (functional magnetic resonance imaging) to examine how aging impacts brain activation during emotional tasks after the administration of intravenous (IV) citalopram (this is the only SSRI available in this form, and is well tolerated and safe in young and old adults). The investigators will further determine what role genetic differences play in this relationship. The investigators expect to see an increase in brain signal as the concentration of IV citalopram increases. However, the investigators propose that the brain signal in older adults will not be as strong as in younger adults. Furthermore, the investigators expect that participants genetically predisposed to have fewer serotonin transporters (the site of action of SSRIs) will show greater decreases in brain activation with citalopram.

Clinical Details

Official title: Pharmacodynamics of Intravenous Citalopram in the Elderly: a Functional Magnetic Resonance Imaging Analysis

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)

Primary outcome: BOLD fMRI Response

Secondary outcome: Genetics and Cognitive/Emotional Change

Eligibility

Minimum age: 20 Years. Maximum age: N/A. Gender(s): Male.

Criteria:

Inclusion Criteria:

- Male aged 60 or older (elderly group)

- Male aged 20-40 (younger adult group)

- English speaking

- Right-handed

- Non-smoker

- Score of 27 or greater on the Mini Mental State Exam

Exclusion Criteria:

- Unstable medical, cardiac, or neurological illness (including stroke, brain tumour,

epilepsy, significant head injury, Alzheimer's, Parkinson's or Huntington's disease)

- Laboratory results indicating unanticipated illness or intolerability of blood

drawing procedures or of study drug

- Current or lifetime Axis-I psychiatric diagnosis on the DSM-IV/SCID (i. e., Module A:

Mood, Module F: Anxiety, Module B & C: Psychosis)

- History of drug or alcohol abuse within one year, or lifetime history of alcohol or

drug dependence (i. e., SCID Module E: Substance Abuse, or clinically significant urine toxicology screen)

- History of non-tolerance to SSRI therapy; including history of SSRI-related syndrome

of inappropriate antidiuretic hormone secretion (SIADH) or sinus bradycardia on ECG (less than 50 beats per minute)

- Contraindication to MRI (as per MRI Contraindication Screening Form)

Locations and Contacts

Christina E Pataky Forsyth, HBSc, Phone: 416-655-4666, Email: cpataky@research.baycrest.org

Rotman Research Institute at Baycrest, Toronto, Ontario M6A2E1, Canada; Recruiting
Christina E Pataky Forsyth, HBSc, Phone: 416-655-4666
Bruce G Pollock, MD PhD FRCPC, Principal Investigator
Christina E Pataky Forsyth, HBSc, Sub-Investigator
Tiffany W Chow, MD, MSc, Sub-Investigator
Aristotle Voineskos, MD PhD FRCPC, Sub-Investigator
Howard Aizenstein, MD, PhD, Sub-Investigator
Robert Bies, PharmD, PhD, Sub-Investigator
Cheryl Grady, PhD, Sub-Investigator
James Kennedy, MD, Sub-Investigator
A. Randy McIntosh, PhD, Sub-Investigator
Laura Wagner, PhD, RN, Sub-Investigator
Additional Information

Starting date: April 2009
Last updated: November 4, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017